CD46

Across TCGA pan-cancer cohorts, CD46 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CD46 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CD46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD46 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV and BLCA are the cancer types where CD46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.304	0.691	.030	18	view →
BLCA	DFS	Median	All	0.867	0.327	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CD46–OV (OS)

Open the OV breakdown →